VCNX News and Press, Vaccinex Inc. From 02/07/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/PhotobyTawat Vaccinex (NASDAQ: VCNX ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Instead, it looks like today’s gains...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: photo.ua / Shutterstock.com It’s time to start the day with a breakdown of the biggest pre-market stock movers to watch on Tuesday! Moving stocks this morning are earnings reports, a takeover offer, and f...

ROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that its licensee, Surface Oncology (NAS...

ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced that on November 23, 2022, the company c...

Vaccinex press release ( NASDAQ: VCNX ): Q3 GAAP EPS of -$0.11. Revenue of $0.05M (flat Y/Y). Cash and cash equivalents and marketable securities on September 30, 2022 were $7.2 million, as compared to $8.6 million as of December 31, 2021. For further details see...

Promising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the Phase 1b/2 KEYNOTE B84 oncology and Phase 1/2a SIGNAL-AD Alzheimer’s s...

ROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D), and its collaborators at Emory Un...

Vaccinex press release ( NASDAQ: VCNX ): Q2 GAAP EPS of -$0.13. Cash and Cash Equivalents and Marketable Securities. Cash and cash equivalents and marketable securities on June 30, 2022 were $11.4M, as compared to $8.6M as of December 31, 2021. For further details se...

Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA ® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in Nature Medicine Patient enrollment continues in the Phase 1/2a ...

Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroinflammatory diseases including Alzheimer’s ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSW...